Upadacitinib (Rinvoq®) for Active Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA)
Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for upadacitinib (Rinvoq) for the treatment of patients 2 years of age and older with active polyarticular course juvenile idiopathic arthritis (pcJIA) who have had an inadequate response or intolerance to methotrexate. Upadacitinib may be used as monotherapy or in combination with methotrexate.